Joel M. Gelfand, MD, MSCE, named Chief Medical Editor of Healio Psoriatic Disease
Click Here to Manage Email Alerts
Healio Psoriatic Disease, the first publication focused on informing health care professionals about the burden of psoriatic disease and the understanding of psoriasis as a systemic disease, has named Joel M. Gelfand, MD, MSCE, as its Chief Medical Editor.
“We are thrilled to welcome Dr. Gelfand as Chief Medical Editor of Healio Psoriatic Disease,” Joan-Marie Stiglich, ELS, Chief Content Officer for Healio, said in a press release. “Along with being at the forefront of psoriasis research, education and patient treatment, he brings an abundance of energy and enthusiasm that will serve the publication and our readers well.”
Gelfand is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety and clinical trials. He is professor of dermatology and epidemiology (with tenure) in the Perelman School of Medicine at the University of Pennsylvania. He is also vice chair of clinical research, medical director of the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center at Penn Medicine.
Gelfand is the author of more than 260 scientific publications, editorials, reviews and textbook chapters. He is a past associate editor of Pharmacoepidemiology and Drug Safety, past editorial board member of Journal of the American Academy of Dermatology and currently deputy editor of Journal Investigative Dermatology.
He is the recipient of the American Skin Association’s Psoriasis Achievement Award, Penn’s Marjorie Bowman New Investigator Research Award and the Lady Barbara Colyton Prize for Autoimmune Research, Penn’s Department of Biostatistics and Epidemiology’s epidemiology teaching award, and the National Psoriasis Foundation’s inaugural award for scientific achievement.
He is an elected member of the American Society for Clinical Investigation, co-chairs the NPF’s COVID-19 task force and is a member of the board of directors for the International Psoriasis Council. He is a co-author of the AAD-NPF joint guidelines of care for psoriasis. He has given more than 10 named lectureships and keynote addresses, including the Society for Investigative Dermatology’s Eugene M. Farber lecture and the American Academy of Dermatology’s Marion B. Sulzberger lecture.
He has received grant support from NIH, FDA, PCORI, the Dermatology Foundation, the American Skin Association, the NPF and numerous pharmaceutical companies to support his independent research program. The overarching goal of his research and clinical practice is to improve outcomes in the skin and joints for patients with psoriasis, while lowering the risk for diabetes, CV disease and mortality.
“I am delighted to work with the outstanding editorial professionals at Healio to help communicate key advances in psoriasis to the thousands of dermatologists, rheumatologists and other medical professionals worldwide who regularly read Healio Psoriatic Disease and are dedicated to improving patient outcomes,” Gelfand said.
Healio Psoriatic Disease features coverage of the latest peer-reviewed research, meeting news highlights and FDA approvals related to psoriatic disease and other dermatological conditions.